Balance Sheet
Cash Flow Statement
Beginning Cash BalanceBeginning Cash BalanceCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Calidi Biotherapeutics (CLDI) Depreciation & Amortization (CF) (2022 - 2025)

Calidi Biotherapeutics' quarterly Depreciation & Amortization (CF) came in at $100000.0 in Q4 2025, little changed year-on-year from $100000.0 in Q4 2024, and little changed quarter-over-quarter from $100000.0 in Q3 2025.

Calidi Biotherapeutics has reported Depreciation & Amortization (CF) for 4 years, with the latest figure at $100000.0 in Q4 2025.

  • For the quarter ending Q4 2025, Depreciation & Amortization (CF) changed 0.0% year-over-year to $100000.0; the trailing twelve-month figure through Dec 2025 stood at $391000.0 (down 2.25% YoY), and the FY2025 full-year result was $400000.0, changed 0.0% from the prior year.
  • Depreciation & Amortization (CF) for Q4 2025 stood at $100000.0, roughly flat from $100000.0 in the prior quarter.
  • The five-year high for Depreciation & Amortization (CF) was $100000.0 in Q3 2022, with the low at $91000.0 in Q1 2025.
  • Average Depreciation & Amortization (CF) over 4 years is $99285.7, with a median of $100000.0 recorded in 2022.
  • Year-over-year, Depreciation & Amortization (CF) advanced 1.01% in 2024 and retreated 9.0% in 2025.
  • Tracing CLDI's Depreciation & Amortization (CF) over 4 years: stood at $100000.0 in 2022, then decreased by 1.0% to $99000.0 in 2023, then rose by 1.01% to $100000.0 in 2024, then changed by 0.0% to $100000.0 in 2025.
  • The last three Depreciation & Amortization (CF) figures came in at $100000.0 (Q4 2025), $100000.0 (Q3 2025), and $100000.0 (Q2 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Depreciation & Amortization (Qtr)
1 Quantum Biopharma 1,638,563.89 Bn 1,638,563.89 Bn - -
2 Alterity Therapeutics 767,934.24 Bn 767,934.20 Bn - 1,395.22
3 Legend Biotech 2,937.00 Bn 2,936.10 Bn 242.10 Mn -
4 Nanobiotix 2,282.79 Bn 2,282.72 Bn - -
5 Akari Therapeutics 2,169.69 Bn 2,169.69 Bn - -
6 Vertex Pharmaceuticals 110.41 Bn 103.16 Bn 2.59 Bn 55.90 Mn
7 Regeneron Pharmaceuticals 66.44 Bn 57.69 Bn 3.31 Bn 123.20 Mn
8 Evaxion A 65.44 Bn 65.42 Bn - -
9 Alnylam Pharmaceuticals 39.53 Bn 36.52 Bn 959.66 Mn 13.55 Mn
10 Calidi Biotherapeutics - - - 100,000.00

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 100,000.00
Dec 31, 2025 100,000.00
Sep 30, 2025 100,000.00
Sep 30, 2025 100,000.00
Jun 30, 2025 100,000.00
Jun 30, 2025 100,000.00
Mar 31, 2025 91,000.00
Mar 31, 2025 91,000.00
Dec 31, 2024 100,000.00
Dec 31, 2024 100,000.00
Sep 30, 2024 100,000.00
Sep 30, 2024 100,000.00
Jun 30, 2024 100,000.00
Jun 30, 2024 100,000.00
Mar 31, 2024 100,000.00
Mar 31, 2024 100,000.00
Dec 31, 2023 99,000.00
Dec 31, 2023 99,000.00
Sep 30, 2023 100,000.00
Sep 30, 2023 100,000.00
Jun 30, 2023 100,000.00
Jun 30, 2023 100,000.00
Mar 31, 2023 100,000.00
Mar 31, 2023 100,000.00
Dec 31, 2022 100,000.00
Dec 31, 2022 100,000.00
Sep 30, 2022 100,000.00
Sep 30, 2022 100,000.00